Alexander Oksche

USPTO Granted Patents = 10 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Cambridge, GB (2021)
Limburg, DE (2015 - 2023)

Company Filing History:

Harm Reduction Therapeutics, Inc.

patents

4. 1 out of 10

Rhodes Pharmaceuticals L.p.

patents

Years Active: 2015-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12458591 - Intranasal pharmaceutical dosage forms comprising naloxone (2025-11-04),

2. 11806428 - Intranasal pharmaceutical dosage forms comprising naloxone (2023-11-07),

3. 11020343 - Intranasal pharmaceutical dosage forms comprising naloxone (2021-06-01),

4. 10898479 - Dihydroetorphine for the provision of pain relief and anaesthesia (2021-01-26),

5. 10071089 - Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation (2018-09-11),

6. 9861628 - Buprenorphine-wafer for drug substitution therapy (2018-01-09),

7. 9782359 - Opioid composition for treating skin lesions (2017-10-10),

8. 9763931 - Buprenorphine-wafer for drug substitution therapy (2017-09-19),

9. 9370512 - Buprenorphine-wafer for drug substitution therapy (2016-06-21),

10. 9101625 - Buprenorphine-wafer for drug substitution therapy (2015-08-11),

Title: The Innovative Contributions of Alexander Oksche

Introduction

Alexander Oksche is a notable inventor based in Limburg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of intranasal dosage forms. With a total of nine patents to his name, Oksche's work focuses on addressing critical health issues, such as opioid overdosing.

Latest Patents

Among his latest patents is an intranasal pharmaceutical dosage form comprising naloxone. This invention relates to a dosing unit that includes naloxone or a pharmaceutically acceptable salt thereof, in an amount equivalent to at least 0.5 mg naloxone HCl dissolved in an application fluid of a volume of 250 microliters or less. This innovative dosage form is designed for use in the treatment of opioid overdosing and at least one symptom associated with it.

Career Highlights

Oksche has worked with prominent companies in the pharmaceutical industry, including Purdue Pharma L.P. and Euro-Celtique S.A. His experience in these organizations has contributed to his expertise in developing effective pharmaceutical solutions.

Collaborations

Some of his notable coworkers include Derek Allan Prater and Malcolm Walden. Their collaboration has likely played a role in advancing the innovative projects they have worked on together.

Conclusion

Alexander Oksche's contributions to the field of pharmaceuticals, particularly through his patents on intranasal dosage forms, highlight his commitment to addressing critical health challenges. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.